Law Offices of Howard G. Smith announces an investigation on behalf Tesaro, Inc. (“Tesaro” or the “Company”) (NASDAQ: TSRO) concerning the Company and its officers’ possible violations of federal securities laws.

On January 12, 2018, Tesaro announced that it had updated the U.S. labeling for Varubi (rolapitant), indicated for the prevention of delayed nausea and vomiting associated with chemotherapy, after receiving reports of "[a]naphylaxis, anaphylactic shock and other serious hypersensitivity reactions . . . in the postmarketing setting, some requiring hospitalization." The Company further disclosed that it "has issued a Dear Healthcare Professional (DHCP) letter."

On this news, shares of Tesaro fell $3.66 per share, or over 5%, to close at $61.86 on January 17, 2018, thereby injuring investors.

If you purchased Tesaro securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.